虽然人们对使用大麻来控制一系列与健康相关的症状越来越感兴趣，但人们对最近大麻使用与各种健康状况相关的趋势知之甚少。我们检查了来自美国年龄≥18岁非机构化成年人的代表性样本的数据来自 2015-2019 年全国药物使用与健康调查（N=214,505）。我们估计了总体患病率的线性时间趋势，以及残疾（即听力、视力、思维、行走、穿衣、办事困难）和寿命（即支气管炎、癌症、糖尿病、肝炎、肾脏疾病）和使用逻辑回归分析当前（即哮喘、抑郁、心脏病、高血压）健康状况。使用具有逐年状态交互项的模型来评估不同的时间趋势，并根据人口特征进行调整。从 2015 年到 2019 年，有或没有检查过每种残疾和健康状况的成年人的大麻使用量显着增加。然而，听力困难（相对于没有听力困难）的患者增加得更快（增加 89.8% [4.9% 至 9.3%] vs 增加 37.9% [8.7% 至 12.0%]，p=0.015）、行走困难（84.1%）增加 [6.3% 至 11.6%] 对比 36.8% 增加 [8.7% 至 11.9%]，p<0.001)，2-3 项损伤（75.3% 增加 [9.3% 至 16.3%] 对比 36.6% 增加 [8.2% 至 16.3%] 11.2%]，p=0.041）和肾脏疾病（增加 135.3% [3.4% 至 8.0%] vs. 增加 38.4% [8.6% 至 11.9%]，p=0.045）。鉴于大麻的潜在副作用，预防减少危害的工作应重点关注使用风险越来越高的群体，包括残疾人和肾病患者。版权所有 © 2023。由 Elsevier Inc. 出版。

While there is increasing interest in the use of cannabis to manage a range of health-related symptoms, little is known about trends in recent cannabis use with respect to various health conditions.We examined data from a US representative sample of noninstitutionalized adults age ≥ 18 from the 2015-2019 National Survey on Drug Use and Health (N = 214,505). We estimated the pooled prevalences followed by linear time trends, overall, and by disability (i.e., difficulty hearing, seeing, thinking, walking, dressing, doing errands) and lifetime (i.e., bronchitis, cancer, diabetes, hepatitis, kidney disease) and current (i.e., asthma, depression, heart disease, hypertension) health condition status using logistic regression. Models with year-by-condition status interaction terms were used to assess differential time trends, adjusting for demographic characteristics.From 2015 to 2019, cannabis use increased significantly among adults with and without each disability and health condition examined. However, the increase was more rapid among those with (versus without) difficulty hearing (89.8% increase [4.9% to 9.3%] vs. 37.9% increase [8.7% to 12.0%], p = 0.015), difficulty walking (84.1% increase [6.3% to 11.6%] vs. 36.8% increase [8.7% to 11.9%], p < 0.001), 2-3 impairments (75.3% increase [9.3% to 16.3%] vs. 36.6% increase [8.2% to 11.2%], p = 0.041), and kidney disease (135.3% increase [3.4% to 8.0%] vs. 38.4% increase [8.6% to 11.9%], p = 0.045).Given the potential adverse effects of cannabis, prevention and harm reduction efforts should focus on groups at increasingly higher risk for use, including those with disabilities and kidney disease.Copyright © 2023. Published by Elsevier Inc.